Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, and Chief Medical Officer of Caladrius Biosciences, delivers a thorough overview of biopharmaceutical research and product development.
Dr. Losordo has spent decades digging deep into the many and various biological science issues that are relevant to advanced medical research. His work has made a significant impact in the areas of angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, as well as vascular biology in general.
Dr. Losordo’s company, Caladrius Biosciences, Inc., is a noted clinical-stage biopharmaceutical company featuring multiple technology platforms that are specifically targeted to certain cardiovascular indications as well as autoimmune diseases. In this informative podcast Dr. Losordo gives an overview of his company’s work and their research. He states their primary objective is not to manage disease but to actually restore health.
He outlines many of their late stage programs in the area of cardiovascular disease, clinical trials, and progress they have made. In prior studies they have found that just a single dose of their therapies makes people better long term. Trials are promising and he expects continued approvals as they bring more products to the market.
Caladrius is committed to the development of innovative products for cardiovascular and autoimmune diseases that carry great potential to restore health to people with chronic, often severe, illnesses, to address many unmet medical needs.
The biopharmaceutical expert discusses blood vessel regeneration, and the research they are doing in this area of angiogenesis. He talks about their work with patients and how their process works, in detail, explaining how the cells are injected and how angiogenesis begins. Dr. Losordo discusses their experimentation with cells and the dramatic successes they see in the repair of ischemic tissue. Dr. Losordo talks about some of the many regulatory issues that impact the medical and biological science development industries. He outlines how their refractory angina program has been designated with a high designation for accelerated approval.
Dr. Losordo’s successful career in regenerative medicine therapeutics has received significant backing. He has obtained over $35 million in National Institutes of Health funding for discovering and developing new therapeutic concepts in the laboratory that provide the basis for clinical studies that may lead the way to medical breakthroughs.